DarshanTalks Podcast cover art

All Episodes

DarshanTalks Podcast — 344 episodes

#
Title
1

Sponsoring Cannabis Research

2

The New Era of Personal Consent Decrees

3

Why Private Membership Associations Fail FDA Scrutiny

4

The Hidden Reason Sites are Firing Recruiters

5

Don’t Let Your PI Walk Away With Your Study

6

Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs

7

"Basically Employees" Isn't a Legal Category (And the OIG Knows It)

8

The Hidden Legal Risks of AI Sponsor Protocols

9

The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable

10

Is AI replacing your Doctor?

11

Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)

12

6 Categories of "Bulk Data" That Could Land You in Federal Court.

13

The Utah Experiment: The Dangerous New Frontier of AI Prescribing

14

Is Your DTC Program a Kickback Trap?

15

The Hidden Death Sentence for Trial Sites

16

FDA "Screams": The Real Reason Your Snack Is At Risk

17

2 Laws More Dangerous Than HIPAA for Patient Engagement

18

"Invite-Only" Compliance Is Over: Is Your Cosmetic Company Ready?

19

Audit-Proof Your Site: The Training Gap Killing Your Contracts

20

15 Years in Prison for Marketing Fraud

21

Is your "Clinical Decision Support" tool actually an unregulated medical device?

22

The FDA’s New Political Enforcement Strategy

23

Why Your "Physician-Only" Ads Aren't Safe from Regulators

24

The Messy Reality of AI Prescriptions

25

Why Your Consultant’s Report Is a Legal Liability

26

Stop Reporting Results? The NIH’s "Get Out of Jail Free" Card

27

Final LGBTQ Individuals in clinical research

28

When the FDA Plays Politics

29

Your Site’s Background Check is Illegally Incomplete - Here is why

30

Is Your Off-Label Use Now a Federal Crime?

31

10,000 Specialists: A Futurist’s Vision for AI Healthcare

32

The Battle Over Weight Loss and Compounded Drugs

33

Why Cosmetic Ingredient Names Matter and What MOCRA Really Means - Interview with Heather Bustos

34

Compliance Isn’t a Deal Killer… Until It Is - Interview with Stephanie Trunk

35

Cosmetic ingredients the FDA doesn’t want you to use

36

Why Federal Agencies Are Targeting Executives

37

Why the New Food Pyramid Matters to You

38

Ex FDA Commissioner Robert Califf on FDA Authority, Politics, and the Health Crisis No One Wants to Name

39

Buying a Med Spa? GLP-1 Compliance Can Kill the Deal

40

New crown jewel valuing patient data

41

Your Staff is trained, but can you prove it?

42

What Happens When a Sponsor Walks Away Early?

43

Cosmetic Claims the FDA Hates

44

Biggest Legal Mistakes in Influencer Marketing

45

Your Mood, Energy, and Sleep Claims Might Be Regulated

46

Device Fail: The Legal Anatomy of a Faulty Implant Scandal

47

5 Documents the FDA Will Demand on Site — Are You Ready?

48

Cosmetic Marketing Mistakes That Trigger Regulators

49

Why Your Clinical Trial Contract Is Leaving Cash on the Table

50

Why Testimonials Can Get Your Brand Sued

51

How to Get Sponsors to Pay Faster than Net 90

52

Compliance Mistakes That Kill Pharma and Biotech Deals

53

Balance FDA Rules with FTC Advertising Requirements

54

Key Clauses in PI Contracts to Review

55

Compliance guru talks practical Insights on Speaker Programs

56

Trends in Small Life Sciences Transactions

57

Protect Your Site If a Sponsor Terminates Early

58

Are Pharma Chatbots Putting You at Regulatory Risk?

59

Are Your Cosmetic Company Records Ready for FDA Audits?

60

When Medical Affairs Becomes Commercial in Disguise

61

Serious Adverse Event Reporting Under MoCRA

62

Key SOPs for Clinical Trials

63

Payer Presentations Can Trigger Enforcement

64

Pharmacies v manufacturers

65

Is Clinical Research Ready for the new FDA?

66

Is your cosmetics company FDA-registered?

67

Will AI Replace Doctors in clinical research?

68

Risks in Direct-to-Patient Engagement

69

Inside 340B: Challenges, Controversies, and Opportunities

70

IRBs in 2025: What’s Really Changing?

71

3 Red Flags in Telemedicine Partnerships

72

What do PBMs do?

73

How AMCs Build Stronger Compliance Cultures Together

74

How One DME Scheme Cost Medicare $61 Million

75

FDA to Step Up Enforcement on Pharma Advertising

76

Top 5 Factors Determining AMC Funding

77

New Series Drop: Exploring AMCs in Clinical Research

78

Why Choose a Licensed Attorney Over a Consultant?

79

Marketing Problems by Hims & Hers and Lilly

80

Should Sponsors Share Site Feedback?

81

AI Marketing Playbook for Drug Companies

82

Should Sites Be Ready on Standby?

83

Eastern District of PA Targets Pharmacies

84

Telehealth Done Right

85

DOJ and HHS Launch FCA Fraud Task Force

86

Should Sponsors Cover Malpractice Insurance?

87

Instagram Post that Sparked FDA Warning Letter

88

Why Are So Many Doctors Getting Arrested?

89

How to Run Compliant Pharma Speaker Programs

90

​​Are You Picking the Wrong KOLs?

91

How KLF’s Client Base Evolved Over 20 Years

92

FDA Pushback on Accelerated Gene Therapy Approvals

93

Your DEI Program Could Trigger an FCA Case

94

Teva’s Charity Partnership Scrutinized

95

Is There a “Right” Way to Calculate FMV?

96

Can Non-Physicians Own Clinical Trial Sites?

97

The KLF Story You Haven’t Heard

98

Why Telehealth Platforms Are Getting Sued

99

Should Clinical Trial Sites Be Paid Differently?

100

How to Build an AI Compliance Program

101

What the Big Beautiful Bill Means for Trial Sites

102

Co-Pay Mistakes Can Trigger DOJ Action

103

NIH Grant Denials Ruled Discriminatory?

104

Are Speaker programs supposed to be salesy?

105

DTP Compliance Just Got Tricky

106

Should You Use AI to Draft Informed Consent?

107

Could You Survive a Surprise Pharmacy Audit?

108

Self-Reporting in Clinical Trials

109

$14M Fine Says This “Free” Offer Wasn’t Legal

110

Nonprofit Pharma Exists. Here is how it works

111

FTC Rules for Pharma Companies

112

Whistleblowing in Clinical Trials: Is It Worth the Risk?

113

The Right Way to Do Medical Affairs on LinkedIn

114

Are We Paying Clinical Trial Patients Enough?

115

Pharma Ads Are Getting Canceled

116

Unpacking Screen Fail Payments in Research

117

Post-Trump Antitrust Rules Are Crushing Pharma Deals

118

7 Must-Know Steps to transfer medical device ownership

119

Responding to Site Findings

120

Is Your Medical Website Illegal?

121

Price Fixing in Clinical Research

122

DOJ Cracks Down on Pharmacy Fraud

123

Protect Your DTP Strategy

124

AI Clinical Trial Negotiators

125

SOPs: How Many is Too Many?

126

Is DTP Pharma’s Next Big Move?

127

Hackers Are Stealing Your Personal Health Data

128

How a “Medical Education” Program Became a $202M Fraud

129

Webinar Recap: What Sponsors Must Know About Fraud

130

AI-Powered Engagement is a Minefield

131

Webinar Update: Fraud Prevention Strategies Every Sponsor Needs

132

Are Your Promotional Claims Putting Your Company at Risk?

133

Privacy Dangers Lurking in Clinical Trial Mergers

134

The FDA's Crisis Is Now Your Problem

135

Broken FDA, Big Consequences

136

You are now the Healthcare Provider - The Future of Health Insurance: Trends, Challenges, and Innovations

137

Essential Due Diligence Steps for Clinical Research M&A

138

Is AI Telemarketing Strategy Illegal?

139

No Clinical Trial Waste

140

The Real Meaning of Audit-Readiness in Clinical Research

141

Ordinary People Are Changing Medicine

142

Investor Influence Can Trigger FCA Violations

143

Sponsor to Organization vs. Direct Investigator Agreements: Pros & Cons

144

Clinical Trial Site M&A: What Most Get Wrong

145

Future-Proof Sites: SOS Insights Revealed

146

Why Food M&A Deals Collapse—And How to Prevent It

147

Non-Compliance Led to QOL Medical's $47M Settlement

148

FDA Regulatory Submissions: Challenges, Trends, and Future Predictions

149

How to do a VR promo check - Carly Schaecter gives us her advice

150

Diversity Matters in Clinical Trials

151

EMA’s LLM Guidelines Impact Life Sciences

152

How to Network Like a Pro at Conferences

153

Getting Ready for SOS 2025: FDA 483s, SOPs, and Site Survival

154

Maximizing Site Value

155

5 Key Areas to Review in Clinical Trial Agreements

156

Discussing Stem Cell Research Opportunities with a Research Site Owner

157

Quality Management: A Must in Clinical Trial Contracts

158

AI-Powered Chatbots in Pharma Sales and Education

159

Will New Tariffs Disrupt Your Next Pharma Deal?

160

Protecting Patient Data in a Changing Regulatory Landscape

161

Off-Label Promotion Changes in 2025

162

Turning Physicians into Leaders

163

Key Regulatory Agencies in Pharma M&A

164

Does E6 (R3) Blur the Line Between GCP and Privacy Laws?

165

RFK Jr. Confirmed as HHS Secretary: What It Means for Healthcare Policy

166

America’s Research Future in Jeopardy

167

Trump Administration’s NIH cuts: Will they cripple US medical research?

168

DEI Under Trump: What It Means for Clinical Trials

169

CAPA & RCA: A Must for Pharma M&A

170

Trump Targets Indirect Costs in NIH Funding

171

The USAID Halt and Its Consequences for Clinical Research

172

Ebola Vaccine Trial in Record Time!

173

Your Clinical Trial Site M&A Agreement is Exposing You to Risk

174

What Does ICH E6 R3 Say About Returning Data to Participants?

175

Navigating the Ongoing HHS Communication Freeze

176

Ordinary People Are Changing Medicine

177

Trump’s First 10 Days: The Impact on Clinical Trials

178

Selling a Business with Issues

179

Breaking Down GCP E6(R3)

180

AdvaMed 7 rules for Essential AI Innovation

181

Teva’s Case Should Shape Your Pharma Strategy

182

AI’s Impact on Healthcare: Liability, Ethics, and Responsibility

183

Four Types of Research related Grant Fraud

184

Defining Scope in Due Diligence Transactions

185

Clinical Trial Checklist

186

Presidential Changes and Impact on Drug Related Misinformation

187

Prep for Selling Your Company!

188

Top Tips for Starting a Clinical Trial Site

189

When Drug Reps Visit: Darshan Reacts

190

Is Pfizer competing with your pharmacy?

191

Talking to a Functional Medicine Doctor

192

Four Types of Research related Grant Fraud

193

Leveraging AI and RWD to Reshape Drug Trials!

194

DCTs in Oncology: Can They Work?

195

Marketing Due Diligence in Stem cell M&A Transactions

196

Why Are PBMs Blocking Your Meds? - Darshan reacts

197

Misleading Ads: Ad laws and Consumer Protection for Marketers

198

5 Common Clinical Trial Site Failures

199

Faster FDA Recalls

200

IRB Challenges and Updates for 2024

201

Is the Polio Vaccine Safe?

202

FDA blue print to discuss off label topics

203

Opportunities AI provides in Clinical Research

204

Telehealth and Biohacking: A Risky Combination

205

Is the FDA’s Response to AI Falling Behind?

206

Healthcare Is in Crisis: How do we fix it?

207

Will RFK Break Pharma?

208

Fake data in Clinical Trials

209

Darshan Fixes Big Pharma Misconceptions

210

How Trump’s Tariffs will Disrupt Clinical Trials and Drug Marketing?

211

Why China is Targeting Top Scientists!

212

Trump’s Bold Picks Shake Up Life Sciences

213

3 Regulatory Opportunities in Clinical Trials!

214

Don't Take Non-Prescription Ozempic or other Weight Loss Drugs

215

Clinical Trial Principal Investigator Duties in Clinical Trials

216

Supreme Court Redefined Pharma Marketing Rules

217

AI concerns in M&A for Life Sciences

218

Trump Teams Potential Changes to Healthcare

219

Can AI Rewrite the Rules of Clinical Trials?

220

Ad Promo Review in Pharma - How Far is Too Far?

221

Why Staff Training Problems are a liability for Your Clinical Trial site

222

Neuralink: Breakthrough or Marketing Hype?

223

Telehealth Compliance Crisis: DOJ exposes $2.75B Fraud!

224

Should You Go In-House or Outsource Your Advertising Compliance?

225

Research fraud tainting pharma per Nature Article

226

Influencers are NOT KOLs. Know your Needs!

227

AI and Clinical Trials: Faster Results, Bigger Risks?

228

Eli Lilly’s Unexpected Shift on Use of Mounjaro!

229

Are CROs Losing Relevance in the Age of DCTs?

230

Managing Risks in Life Science Mergers and Acquisitions with Strategic Insurance

231

Can a Pharmacist Override Your Doctor's Prescription?

232

FDA Concerns About AI’s impact on Good Clinical Practices

233

Patient Advocates Could Cost You Millions

234

Managing Risks in Life Sciences Mergers and Acquisitions

235

How do pharmacists’ read doctors’ cursive letters?

236

AI Data Ownership in Pharma

237

Role of Tech Transfer in Clinical trial agreements

238

Why are medicine names so complicated?

239

Fixing Congruency Reviews in 8 Minutes

240

The Dark Side of Med Device Kickbacks

241

Which Hair Loss Treatment Is Right for You?

242

Analyzing the Publication Rights Clause in CTAs

243

What Really Starts Pharmacy Investigations?

244

Is your clinical trial AI racist?

245

Another Pharmacy owner Jailed in Fraud Case

246

Navigating FDA's clinical trial expectations after approval

247

Legal Minute: Do dietary supplements interact with drugs?

248

How Expert Pharma Marketers Navigate Privacy

249

Hiring New Employees in PharmaTech Companies

250

3 Hidden Dangers of Telehealth Marketing

251

Why a food lawyer would stop your restaurant’s marketing?

252

Legal Minute: Why are there chemo drug shortages?

253

Are Pharma Giants Ignoring Clinical Trial Site Issues?

254

Why Adverse Events Go Unreported in Clinical Trials

255

Who are patient advocates?

256

Why Drug Accountability Matters in Clinical Trials

257

Legal Minute: What do I do if my med is on shortage?

258

5 reasons not to use AI in creating pharma marketing content

259

8 essential elements of a valid prescription

260

No more lawyers in PRC?

261

Legal Minute: 4 Ways to Get Unapproved Drugs Legally!

262

The 4 Building Blocks of Using AI in any Pharma Marketing Strategy

263

Legal Minute: Why Clinical Trials Are Right for You!

264

Why Clinical Researchers Are Flocking to MedSpas

265

Legal Minute: Why You Should Never Trust a Celebrity with Your Health

266

Essential tips for pharmacy shutdowns

267

Why Clinical Researchers Are Flocking to MedSpas

268

Legal Minute: 5 Surprising Benefits of Ozempic!

269

Who Owns AI Generated Content in Pharma?

270

Legal Minute: Why does my drug cost so much?

271

AI for Promotions in FDA-Regulated Industries

272

Legal Minute: Billion-Dollar Speaker Scheme!

273

Off-Label Risks: Compliance Matters Now More Than Ever

274

6 Must-Knows Before Buying a Drug or Device Company

275

Legal Minute: Are there chemo drug shortages?

276

Legal Minute: Don’t Ignore State Registrations

277

Legal Minute: 6 Crucial Mistakes in Informed Consent

278

Legal Minute: What is informed consent in clinical trials?

279

Stop Risky Ads: Class Actions Could Cost You

280

Legal Minute: How do drugs work?

281

5 Surprising Causes of Life Science Deal Failures

282

Legal Minute: Is pharma bribing your doctor?

283

Legal Minute: Drug Registrations that can’t be ignored

284

Legal Minute: Why do pharmacies take so long to fill prescriptions?

285

Legal Minute: 3 Steps to Avoid Food Recalls

286

Legal Minute: Are dietary supplements as good as drugs?

287

Legal Minute: Clinical Trial Record Retention Disasters

288

Legal Minute: Why is your medicine so expensive?

289

McKinsey’s 2030 vision: A challenge for medical affairs

290

Legal Minute: 3 must-do takeaways for collecting diversity data in clinical trials

291

Legal Minute: Are Brand and Generic Drugs Truly Different?

292

Legal Minute: Who's REALLY Responsible for a Clinical Trial Congruency review?

293

This Drug Ad is FULL of Red Flags (We Expose Them All!)

294

7 ways to challenge FDA’s regulation of LDTs

295

Legal Minute: eBay’s $59 Million Drug-Making Problem

296

Legal Minute: Neuralink is a Game-Changer: 3 Lessons You Can't Afford to Miss

297

Legal Minute: Off-label marketing not ok again?

298

Don't Become the Next Fraud Headline: Lawyer Reveals Compliance Traps

299

Legal Minute: 3 Insider Secrets for a Successful Medical Device Recall

300

Key elements of a successful congruency review for clinical trial agreements

301

Why Private Equity firms are betting big on clinical research sites

302

5 Ways to Legally Share Off-Label Information

303

DOJ's "Get Out of Jail Free" card for pharma and device mergers?

304

Legal Minute: 5 factors to get your digital speaker program approved

305

Legal Minute: Decoding the FDA's prescription drug use related software guidance

306

Congruency Review: The Game Changer

307

Legal Minute: 5 hacks to fast-track your speaker program reviews

308

Selecting your ideal subject recruitment partner

309

Your digital sales team’s success depends on these 5 compliance rules

310

Legal Minute: 3 FTC rules for winning comparative claims

311

The risks and rewards of Clinical Research as a Care Option

312

3 game changing ways the FDA says AI will transform drug development

313

Legal Minute: Comparative claim review by NAD

314

5 foolproof ways to get your digital speaker program approved

315

Legal Minute: Prepare your Cosmetics Company for 2024

316

How to get PRC to approve your ads quickly

317

Legal Minute: 4 Must Do's When Choosing a Predicate Device for Your 510(k)

318

Legal Minute: FDA's Vision for the Future of IT

319

Legal Minute: FTC announces major revamp in 2024 enforcement strategy

320

23andMe data breach: Is your genetic data the next big target for hackers?

321

Ultimate Guide for Clinical Trial Publishing Rights in Large Academic Centers | Istvan Fekete

322

FDA's off-label trap: 7 reasons for uncertainty

323

Legal Minute: 3 ways #pharmacies are fighting high generic drug prices!

324

Pharma Industry Secrets: The Surprising Truth About DEI | Celia Daniels

325

Case Study: Academic Research Center Misconduct

326

Legal Minute: FTC Cracking Down on AI- 3 Must-Know Tips to Stay Compliant

327

Project management as a clinical research game-changer

328

Legal Minute: 5 Must-Do’s for Virginia Tech’s FBRI to combat research fraud

329

Legal Minute: Pharmacy Closing Checklist: 7 Must Do's

330

FDA Approval for LDTs Made Easy

331

Legal Minute: Pharmacist fraudster found guilty

332

AI's Complex Role: Creator, Copycat or Both?

333

FDA warns 8 companies including Walgreens selling unapproved eye products

334

Why the FDA’s plan to use one pagers will fail

335

Supercharge your Marketing Approval Process based on these Concept Review Tips

336

Testosterone parties and unapproved biohacks: Is it worth the risk? #darshantalks

337

Generative AI…confidently spews BS!

338

Testosterone parties and unapproved biohacks: Is it worth the risk? #darshantalks

339

Research Fraudster Banned by the FDA

340

How does CTP regulate tobacco? | Micah Berman

341

60 second reveal: 3 Regulatory authorities that can make or break your pharma or device sale

342

Maximizing FDA meetings: Getting the best out of every encounter | Ashley Preston

343

The role of decentralized trials in the traditional landscape | Isaac Rodriguez- Chavez

344

The Essential Guide to 7 Types of Clinical Trial Agreements